Figure 1 Acute kidney injury and chronic kidney disease

Slides:

Advertisements

Similar presentations

A.M. Thompson, T.G. Pickering Kidney International

Advertisements

RIFLE criteria for acute kidney injury

Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998– DOI: / © 2008.

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 1 Types of coronary artery calcification

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Role of the kidney in glucose homeostasis

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 2 Milestones in paediatric acute kidney injury (AKI) research

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Figure 2 The potential effects of nicotinamide adenine

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Specificity of the various epidermal growth factor (EGF)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Determinants of renal contrast medium enrichment

Figure 3 Localization of ErbB receptors and ligands within the nephron

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Serum phosphate level is associated with

Figure 1 CD36 structure and post-translational modifications

Nat. Rev. Nephrol. doi: /nrneph

Volume 70, Issue 11, Pages (December 2006)

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Figure 1 Acute kidney injury and chronic kidney disease Figure 1 | Acute kidney injury and chronic kidney disease. Acute kidney injury and chronic kidney disease often form a continuum of disease as opposed to being separate entities. The various disease modifiers and risk factors might represent opportunities to intervene and mitigate the poor outcomes associated with these diseases. Modified from Acute Dialysis Quality Initiative 16; www.adqi.org. Modified from Acute Dialysis Quality Initiative 16; www.adqi.org. Chawla, L. S. et al. (2017) Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.2